Novo Nordisk Sheds $50B in Market Cap Amid Rising Competition and Pricing Pressures

Novo Nordisk has experienced a significant downturn, losing approximately $50 billion in market capitalization over the past month. This decline effectively erases much of the valuation gains achieved since the successful launch of its weight-loss drug, Wegovy, in 2021. The primary driver behind this sell-off is emerging clinical data suggesting that rival Eli Lilly's therapies are outperforming Novo Nordisk's current offerings. Additionally, investors are concerned about looming price reductions across the company's core GLP-1 drug franchise. As competition intensifies in the high-growth obesity treatment market, the company faces mounting pressure to maintain its dominant market share. Analysts suggest that the combination of clinical underperformance and pricing headwinds could continue to weigh on the stock's performance in the near term.